Management of thrombophilia in women with PVC

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 46-50

  Kupferminc, J M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CONFERENCE PAPER; DISEASE ASSOCIATION; FETUS WASTAGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; OUTCOMES RESEARCH; PLACENTA; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SOLUTIO PLACENTAE; STATISTICAL SIGNIFICANCE; THROMBOPHILIA;

ABRUPTIO PLACENTAE; DISEASE MANAGEMENT; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; THROMBOPHILIA;

EID: 12544249743     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001;98(6):1041-1044.
2. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000;15(8):1830-1833.
3. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, Blomberg von BME, Jakobs C, Geijn van HP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
4. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
5. Nagy B, Tóth T, Rigó J JR, Karádi I, Romics L, Papp Z. Detection of factor v Leiden in severe pre-eclamptic Hungarian women. Clin genet 1998;53:478-81.
6. Rigo J Jr, Nagy B, Fintor L, Tanyi J, Beke A, Karadi I, Papp Z. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 2000;19:163-72.
7. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999;340:9-13.
8. Pampus van MG, MP van, Dekker GA, Wolf HW, PC Huijgens PC, MMW Koopman MMW, Blomberg BME von, Büller HR. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999;180:1146-50.
9. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000 Jul;96(1):45-9.
10. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden mutation, coagulation inhibitor deficiency, and elevated antiphospholipid antibodies in patients with pre-eclampsia or HELLPsyndrome. Thromb Res 2000;100:363-5.
11. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998;92:457-60.
12. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N, Montanaro S, Paladini D, Martinelli P, Di Minno G. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999;81:349-52.
13. Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolable methylenetetrahydrofolate reductase gene variants in an east Anglian preeclampsia cohort. Hypertension 1999,33:1338-41.
14. Sohda S, Arinami T, Hamada HM, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997;34:525-6.
15. Mello G, Parretti E, Martini E, Mecacci F, La Torre P, Cioni R, Lucchetti R, Fedi S, Gori AM, Pepe G, Prisco D, Abbate R. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis 1999;29:197-203.
16. De Groot CJM, Bloemenkamp KWM, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, De Ronde H, Oei SG, Kanhai HHH, Rosendaal FR. Preeclampsia and genetic risk factors for thrombosis: a case control study. Am J Obstet Gynecol 1999;181:975-80.
17. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002;87:779-85 [Review].
18. Rajkovic A, Catlano PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997;90:168-71.
19. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000;71(4):962-8.
20. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:781-5.
21. Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes,and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995;172(1 Pt 1):125-9.
22. Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002 Mar;186:422-6.
23. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408-12.
24. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocystinemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1248-54.
25. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000;11:963-7.
26. Martinelli P, Grandone E, Colaizzo D, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Hematologica 2001;86:428-31.
27. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, Di Minni G, et al. low birth-weight in neonates of mothers carrying factor V G1691A and factor A 20210 mutations. Hematologica 2002;87:177-181.
28. Infante-Rivard C., Rivard GE., Yotov WV, Genin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca JC. Absence of Association of Thrombophilia Polymorphisms with Intrauterine Growth Restriction. N Engl J Med 2002;347:1925.
29. Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Landsberg JA. Mid-Trimester Severe intrauterine growth restriction Is Associated with a high Prevalence of Thrombophilia. BJOG 2002;109:1373-6.
30. van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG 2000;107:785-91.
31. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998;179:1565-7.
32. Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocystinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-9.
33. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995;35(4):357-62.
34. Kupferrminc MJ, Fait G, Many A, et al. A. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertension in Pregnancy 2001;20:35-44.
35. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998;80:49-54.